A Benefit-Risk Assessment of Sibutramine in the Management of Obesity
Authors:
- Enzo NisoliENEnzo Nisoli
- Michele O CarrubaMCMichele O Carruba
- 1 January 2003
- journal article
- review article
- Published by Springer Nature in Drug Safety
- Vol. 26 (14) , 1027-1048
Abstract
Obesity is a multifactorial, chronic disorder that has reached epidemic proportions in most industrialised countries and is threatening to become a global epidemic. Clinical management of obese...Keywords
This publication has 80 references indexed in Scilit:
- Overweight, Obesity, and Mortality from Cancer in a Prospectively Studied Cohort of U.S. AdultsNew England Journal of Medicine, 2003
- Absence of Cardiac Valve Dysfunction in Obese Patients Treated with SibutramineObesity Research, 1999
- Original Articles Sibutramine Reduces Food Intake in Non‐Dieting Women with ObesityObesity Research, 1998
- SibutramineDrugs, 1998
- Characterization of 5‐HT receptors on human pulmonary artery and vein: functional and binding studiesBritish Journal of Pharmacology, 1997
- Pharmacotherapy for Obesity — Do the Benefits Outweigh the Risks?New England Journal of Medicine, 1996
- Appetite-Suppressant Drugs and the Risk of Primary Pulmonary HypertensionNew England Journal of Medicine, 1996
- Guidelines for the Approval and Use of Drugs to Treat ObesityObesity Research, 1995
- Appetite SuppressantsDrugs, 1992
- The Effect of Weight Reduction on Blood Pressure, Plasma Renin Activity, and Plasma Aldosterone Levels in Obese PatientsNew England Journal of Medicine, 1981